Company intelligence / Profile preview

Robocath

Ownership: Private
Employees: ~70
Development stage: Commercial

Overview

The R-One robotic system demonstrated over 95% technical procedure success with no major adverse cardiovascular events in a prospective multicenter clinical trial. It received CE marking in Europe and has been adopted for commercial use across multiple continents.

Therapeutic areas: CardiovascularNeurology
Modalities: DeviceRobotic-assisted intervention (Device)Digital health platform (if considered a modality)
Industry: Surgical Medical Devices

Partnerships

MicroPort Scientific Corporation (China joint venture/distribution)

Beyond the preview

Go deeper on Robocath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Robocath.

Explore the full profile